<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663195</url>
  </required_header>
  <id_info>
    <org_study_id>#344</org_study_id>
    <nct_id>NCT00663195</nct_id>
  </id_info>
  <brief_title>Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure</brief_title>
  <official_title>Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tottori University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tottori University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of spironolactone on circulating MMP
      levels and insulin resistance in patients with chronic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis.
      Recently, circulating MMPs can be measured and are elevated in patients with chronic heart
      failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF
      animal models. Therefore, the purpose of this study is to evaluate the effects of
      spironolactone on circulating MMP levels in patients with chronic heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMP levels</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Stable Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone + furosemide</intervention_name>
    <description>spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic stable heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kazuhide Ogino</name_title>
    <organization>Center for Clinical Residency Program, Tottori University Hospital</organization>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>fibrosis</keyword>
  <keyword>MMP</keyword>
  <keyword>spironolactone</keyword>
  <keyword>furosemide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

